Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prognostic Value of Measuring Circulating Tumor DNA in a Cohort of Patients With Stage III and IV UADT Cancer, Treated With Curative RADiOtherapy With or Without Concomitant Treatment.

NCT06479070 is registered in ClinicalTrials.gov with Institut de Cancérologie de Lorraine as lead sponsor.

NCT NCT06479070
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06479070 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prognostic Value of Measuring Circulating Tumor DNA in a Cohort of Patients With Stage III and IV UADT Cancer, Treated With Curative RADiOtherapy With or Without Concomitant Treatment.
Lead sponsor
Institut de Cancérologie de Lorraine
Phase
Not applicable
Overall status
Recruiting
Start date
September 30, 2024
Completion date
September 30, 2029
Enrollment
188 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

scc - squamous cell carcinoma, upper aero-digestive tract (uadt) neoplasm